Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	1. To assess the safety and determine maximum tolerated dose of Essential oil blend nebulization by evaluating the toxicities including: type; frequency; severity; attribution and duration. <br/ >2. To assess the efficacy of EOs nebulisation in preventing respiratory symptoms development in asymptomatic and mild disease COVID-19 positive patients <br/ >3. To assess the efficacy of EOs nebulisation in respiratory symptom relief in mild disease COVID-19 positive patients. <br/ >Timepoint: Baseline; Day 3; 5; 7; 10 and !4	1. To assess the safety and determine maximum tolerated dose of Essential oil blend nebulization by evaluating the toxicities including: type; frequency; severity; attribution and duration. <br/ >2. To assess the efficacy of EOs nebulisation in preventing respiratory symptoms development in asymptomatic and mild disease COVID-19 positive patients <br/ >3. To assess the efficacy of EOs nebulisation in respiratory symptom relief in mild disease COVID-19 positive patients. <br/ >Timepoint: Baseline; Day 3; 5; 7; 10 and !4
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
Sept. 8, 2021, 1:30 a.m.	oms	1. To assess the safety and determine maximum tolerated dose of Essential oil blend nebulization by evaluating the toxicities including: type; frequency; severity; attribution and duration. <br/ >2. To assess the efficacy of EOs nebulisation in preventing respiratory symptoms development in asymptomatic and mild disease COVID-19 positive patients <br/ >3. To assess the efficacy of EOs nebulisation in respiratory symptom relief in mild disease COVID-19 positive patients. <br/ >Timepoint: Baseline; Day 3; 5; 7; 10 and !4	1. To assess the safety and determine maximum tolerated dose of Essential oil blend nebulization by evaluating the toxicities including: type; frequency; severity; attribution and duration. <br/ >2. To assess the efficacy of EOs nebulisation in preventing respiratory symptoms development in asymptomatic and mild disease COVID-19 positive patients <br/ >3. To assess the efficacy of EOs nebulisation in respiratory symptom relief in mild disease COVID-19 positive patients. <br/ >Timepoint: Baseline; Day 3; 5; 7; 10 and !4